Evidence map›Paper›PMID 34002000›Full record

ArticleScientific reports2021

Author Correction: Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease.

Kevin A Lidberg, Andrew J Annalora, Marija Jozic, Daniel J Elson, Lu Wang, Theo K Bammler, Susanne Ramm, Maria Beatriz Monteiro, Jonathan Himmelfarb, Craig B Marcus and 2 more

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Kevin A Lidberg *Department of Pharmaceutics, University of Washington, Seattle, WA, USA.
Andrew J Annalora *Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, USA. Andrew.Annalora@oregonstate.edu.
Marija JozicDepartment of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, USA.
Daniel J ElsonDepartment of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, USA.
Lu WangDepartment of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, USA.
Theo K BammlerDepartment of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, USA.
Susanne RammVictorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, Australia.
Maria Beatriz MonteiroDepto Clinica Medica, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, São Paulo, Brazil.
Jonathan HimmelfarbKidney Research Institute, University of Washington, Seattle, WA, USA.
Craig B MarcusDepartment of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, USA.
Patrick L IversenDepartment of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, USA.
Edward J KellyDepartment of Pharmaceutics, University of Washington, Seattle, WA, USA. Edkelly@uw.edu.
Oregon State University · USUniversity of Washington · USHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRPeter MacCallum Cancer Centre · AU

Funding

XENOBIOTIC BIOTRANSFORMATION AND DISPOSITIONP30ES007033 · NIEHS · UNIVERSITY OF WASHINGTON · PI Sheela Sathyanarayana · 1995 to 2026
$42.5M
NIEHS NIH HHS P30 ES007033
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34002000
PMCPMC8128877
OpenAlexW3160086036

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.